Trends in use of continuous glucose monitors among individuals with type 2 diabetes enrolled in Medicare Advantage (2021-2023).
PMID: 41760572 · 2026
JournalJournal of managed care & specialty pharmacy
Year2026
PMID41760572
Abstract
In 2023, the Centers for Medicare and Medicaid Services (CMS) expanded continuous glucose monitoring (CGM) coverage in Medicare among individuals with type 2 diabetes and insulin use; however, little is known about current trends in CGM use among Medicare beneficiaries with type 2 diabetes. To assess trends in CGM use among Medicare beneficiaries with type 2 diabetes from 2021 to 2023 and to compare demographic and clinical characteristics of beneficiaries who used CGMs to those who did not in 2
Official Source
View on PubMed →Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.